Cargando…
QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598910/ http://dx.doi.org/10.1093/neuonc/noab196.757 |
_version_ | 1784600830300651520 |
---|---|
author | Polskin, Lily Pillai, Valentina Vera, Elizabeth Acquaye, Alvina Briceno, Nicole Choi, Anna Christ, Alexa Grajkowska, Ewa Jammula, Varna Leeper, Heather Levine, Jason Lindsley, Matthew Reyes, Jennifer Roche, Kayla Rogers, James Timmer, Michael Boris, Lisa Burton, Eric Lollo, Nicole Panzer, Marissa Penas-Prado, Marta Theeler, Brett Wu, Jing Gilbert, Mark Armstrong, Terri King, Amanda |
author_facet | Polskin, Lily Pillai, Valentina Vera, Elizabeth Acquaye, Alvina Briceno, Nicole Choi, Anna Christ, Alexa Grajkowska, Ewa Jammula, Varna Leeper, Heather Levine, Jason Lindsley, Matthew Reyes, Jennifer Roche, Kayla Rogers, James Timmer, Michael Boris, Lisa Burton, Eric Lollo, Nicole Panzer, Marissa Penas-Prado, Marta Theeler, Brett Wu, Jing Gilbert, Mark Armstrong, Terri King, Amanda |
author_sort | Polskin, Lily |
collection | PubMed |
description | BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS: Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS: The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION: Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology |
format | Online Article Text |
id | pubmed-8598910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85989102022-01-05 QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC Polskin, Lily Pillai, Valentina Vera, Elizabeth Acquaye, Alvina Briceno, Nicole Choi, Anna Christ, Alexa Grajkowska, Ewa Jammula, Varna Leeper, Heather Levine, Jason Lindsley, Matthew Reyes, Jennifer Roche, Kayla Rogers, James Timmer, Michael Boris, Lisa Burton, Eric Lollo, Nicole Panzer, Marissa Penas-Prado, Marta Theeler, Brett Wu, Jing Gilbert, Mark Armstrong, Terri King, Amanda Neuro Oncol 26th Annual Meeting & Education Day of the Society for Neuro-Oncology BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS: Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS: The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION: Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology Oxford University Press 2021-11-12 /pmc/articles/PMC8598910/ http://dx.doi.org/10.1093/neuonc/noab196.757 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
spellingShingle | 26th Annual Meeting & Education Day of the Society for Neuro-Oncology Polskin, Lily Pillai, Valentina Vera, Elizabeth Acquaye, Alvina Briceno, Nicole Choi, Anna Christ, Alexa Grajkowska, Ewa Jammula, Varna Leeper, Heather Levine, Jason Lindsley, Matthew Reyes, Jennifer Roche, Kayla Rogers, James Timmer, Michael Boris, Lisa Burton, Eric Lollo, Nicole Panzer, Marissa Penas-Prado, Marta Theeler, Brett Wu, Jing Gilbert, Mark Armstrong, Terri King, Amanda QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title | QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title_full | QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title_fullStr | QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title_full_unstemmed | QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title_short | QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC |
title_sort | qolp-37. mood disturbance in patients with central nervous system (cns) tumors during the covid-19 pandemic |
topic | 26th Annual Meeting & Education Day of the Society for Neuro-Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598910/ http://dx.doi.org/10.1093/neuonc/noab196.757 |
work_keys_str_mv | AT polskinlily qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT pillaivalentina qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT veraelizabeth qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT acquayealvina qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT bricenonicole qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT choianna qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT christalexa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT grajkowskaewa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT jammulavarna qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT leeperheather qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT levinejason qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT lindsleymatthew qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT reyesjennifer qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT rochekayla qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT rogersjames qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT timmermichael qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT borislisa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT burtoneric qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT lollonicole qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT panzermarissa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT penaspradomarta qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT theelerbrett qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT wujing qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT gilbertmark qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT armstrongterri qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic AT kingamanda qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic |